October 1, 2019
The wholly-owned subsidiary "Zhongshan Kanghai Taisheng Biotechnology Co., Ltd." was registered and established
Zhongshan Kanghai Taisheng Biotechnology Co., Ltd. is a subsidiary of Quacell Biotechnology, Co., Ltd., officially registered in Zhongshan City, Guangdong Province, carrying quality analysis and testing platform and biological drug CMC research and development platform; It focuses on industrial cell culture application research, product development and manufacturing. For the global biopharmaceutical and gene therapy companies, it provides key raw materials and services.
Kanghai Taisheng Biotechnology is located in the Bay Area Zhongshan headquarters, has about 7000 square meters of research and development, manufacturing and office space. It complies with the requirements of ISO and NMPAFDA regulations and has established a GMP standard culture medium manufacturing plant, CMC development and pilot test platform. So as to provide customers with high-quality products and services that meet the regulatory requirements. The company also has a unique R&D platform for cell culture applications focusing on biological drugs and gene therapy. Its innovative technology and superior R&D capabilities are designed to help customers accelerate R&D.
Company high-quality products and services which win nearly 100 biological pharmaceutical and biotechnology companies in the country and abroad customers recognition and trust. Its establishment has won a number of well-known industry risk investment fund, including Shenzhen Capital Group CO., and National Venture Capital. Moreover, the company has been awarded many honours, including Pearl Zhujiang River Entrepreneurial Talent Enterprise, National Winning Project Enterprise in China Innovation and Entrepreneurship Competition, Top 50 "Potential Enterprises" in the Guangdong-Hong Kong-Macao Greater Bay Area, and the Most Potential Leading Enterprise in Asia, etc.
The company is committed to becoming a global leader in industrial cell culture applications.
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
Conclusion | Biofuture2021
BIG EVENETS. Day 2 | Biofuture 2021
BIG EVENETS. Day 1 | Biofuture 2021
Wayne293™ Transient medium was launched